http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201902910-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bca3b113354c50e02fd69af5e5021250 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_398fbb1cb3a234d4641407c462b5a586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8024259c21204e13c5495e0721936ddc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93e9160d7d8a474badab0a2e2387a17b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4600162f2386ce4cb38fbeff57393cab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dae8e1b19b987b01e3f8905a8d29d37 |
| publicationDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201902910-A |
| titleOfInvention | Synergistic combination of nucleic acid oligonucleotides and apoptosis-inducing molecular therapeutic agents |
| abstract | The present invention provides a composition and method for treating cancer, the method comprising administering a combination of an anticancer drug, wherein the combination comprises an apoptosis inducing molecular therapeutic agent and one or more at least one splice variant capable of downregulating an IG20 gene The nucleic acid molecules that are expressed, and not all of the splice variants of the IG20 gene are down-regulated. In one embodiment, the splicing variant of the IG20 gene is a MADD splice variant and the nucleic acid molecule comprises a nucleic acid sequence of exon 13L with the MADD splice variant or an exon 13L with the MADD splice variant siRNA, shRNA and antisense oligonucleotides of the nucleic acid sequence complementary to the mRNA transcript. The invention encompasses a method of treating cancer comprising the use of a combination therapy of a nucleic acid molecule capable of downregulating the expression of at least one splice variant of the IG20 gene and an apoptosis inducing molecular therapeutic agent. |
| priorityDate | 2017-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 383.